News Releases

2011

XXX
Dec.22.2011
Leukotriene Receptor Antagonist "Onon® Dry Syrup 10%" has received approval for the additional indication of allergic rhinitis(57.3KB)
XXX
Dec.13.2011
Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology(27.1KB)
XXX
Dec.08.2011
Launch of an Intravenous Antiemetic Selective Neurokinin-1(NK1)Receptor Antagonist,"PROEMEND® Intravenous infusion 150mg"(80.4KB)
XXX
Nov.30.2011
FDA Acceptance of New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.(56.5KB)
XXX
Nov.14.2011
Announcement of the results from a Phase 2 study of “ONO-5163/KAI-4169”:a calcium sensing receptor agonist(69.5KB)
XXX
Oct.20.2011
Revisions of Consolidated Financial Forecasts(72.3KB)
XXX
Oct.04.2011
Ono to Enter into License Agreements with Merck KGaA(89.0KB)
XXX
Sep.29.2011
Additional Indication Application Filed for a Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting“EMEND® Capsule”for Pediatric Patients Aged 12 and older(62.7KB)
XXX
Sep.29.2011
New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.(111KB)
XXX
Sep.26.2011
Approval received for an Intravenous Antiemetic Selective Neurokinin-1(NK1)Receptor Antagonist,“PROEMEND® Intravenous infusion 150mg”(24.6KB)
XXX
Sep.21.2011
Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 Antibody,ONO-4538/BMS-936558,and ORENCIA®(abatacept),Rheumatoid Arthritis Agent(70.8KB)
XXX
Sep.16.2011
Glactiv® has received approval for the additional indication of combination use with insulin(84.6KB)
XXX
Sep.15.2011
Ono Enters License Agreement with KAI Phamaceuticals,Inc.for KAI 4169(25.3KB)
XXX
Sep.15.2011
Launch of RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg,Once per 4week Oral Osteoposis Treatment in Japan(92.6KB)
XXX
Sep.14.2011
Ono Enters into License Agreement with Servier for Ivabradine(22.7KB)
XXX
Sep.14.2011
Launch of Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan(19.1KB)
XXX
Aug.24.2011
Helsinn Announced to have Initiated Global Pivotal Phase III Clinical Program to Evaluate Anamorelin (ONO-7643/RC-1291) in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia (19.3KB)
XXX
Jul.19.2011
Launch of Rivastach® Patch,for the Treatment of Dementia of Alzheimer's Type (120KB)
XXX
Jul.01.2011
Approval for RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg, Once per 4weeks Oral Osteoposis treatment in Japan (49.6KB)
XXX
Jul.01.2011
Approval for Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan (11.0KB)
XXX
Jun.27.2011
Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec (35.7KB)
XXX
Jun.01.2011
Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue (45.1KB)
XXX
May.20.2011
Approval for Additional Indication Application of Type-2 Diabetes Drug,Glactiv Tablets
-Combination Therapy with Alpha-glucosidase Inhibitors- (14.2KB)
XXX
May.11.2011
Announcement on Financial Results for FY2010
XXX
May.11.2011
Announcement on Introduct of Corporate Officer System,Changes of Members of the Board of Directors and Appointment of Corporate Officers (69.1KB)
XXX
Apr.22,2011
Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease (168KB)
XXX
Apr.06,2011
Announcement on Cancellation of the Company's Own Shares (96.7KB)
XXX
Apr.05,2011
Launch of Orally Disintegrating Tablet of Staybla Tablets 0.1mg, a Drug for Overactive Bladder (16.5KB)
XXX
Mar.29,2011
Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines (54.4KB)
XXX
Mar.25,2011
Announcement on Results and Completion of Acquisition of the Company’s Own Shares (99.7KB)
XXX
Jan.11,2011
Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease (15.3KB)